Potential liver toxicity prompts Lilly to stop Alzheimer's drug study

06/16/2013 | Reuters

Eli Lilly and Co. has discontinued a Phase II trial of its investigational Alzheimer's disease drug LY2886721, a beta secretase inhibitor, after cases of abnormal liver tests were identified. Lilly believes the liver problems are not linked to how the drug works, and it still wants to develop beta secretase inhibitors for Alzheimer's.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC